Insider Trading Arrangements

3 Months Ended

Sep. 30, 2025

The following table describes the written plans for the sale of our securities adopted by our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) during the third quarter of 2025, and one from the second quarter of 2025 that was previously not disclosed, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).

Name and Title

Date of Adoption of Trading Plan

Scheduled Expiration Date of Trading Plan (1)

Maximum Shares Subject to Trading Plan

Carmen Bozic

EVP, Global Medicines Development and Medical Affairs, Chief Medical Officer

5/30/2025

11/21/2025

19,404

Kristen Ambrose

SVP, Chief Accounting Officer

8/08/2025

8/03/2026

7,539(2)

Jeffrey Leiden

Executive Chairman

8/06/2025

1/21/2026

144,644

E. Morrow "Morrey" Atkinson, III

EVP, Chief Technical Operations Officer, Head of Biopharmaceuitcal Sciences and Manufacturing Operations

8/11/2025

4/30/2026

12,709(2)

Ourania "Nia" Tatsis

EVP, Chief Regulatory and Quality Officer

8/21/2025

7/31/2026

24,301(2)

(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.

(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.

Non-Rule 10b5-1 Arrangement Adopted

false

Rule 10b5-1 Arrangement Terminated

false

Non-Rule 10b5-1 Arrangement Terminated

false

Carmen Bozic [Member]

Trading Arrangements, by Individual

Name

Carmen Bozic

Title

EVP, Global Medicines Development and Medical Affairs, Chief Medical Officer